{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T16:41:22Z","timestamp":1774802482791,"version":"3.50.1"},"reference-count":64,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,12,19]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gabapentin is currently used \u2018off-label\u2019 in children and adolescents with chronic neuropathic pain, and reliable evidence of its effects and optimal dosing are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The GABA-1 trial aims to compare the efficacy and safety of gabapentin liquid formulation relative to tramadol and to explore the pharmacokinetics of both drugs in the treatment of chronic, neuropathic or mixed pain in the paediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The trial is a multicentre, double-blind, double-dummy, randomised, active-controlled, non-inferiority trial. Participants aged from 3 months to &lt;18 years of age with moderate to severe (\u22654\/10 in age-appropriate pain scales) chronic neuropathic or mixed pain will be recruited in 14 clinical sites in eight European countries. A total of 94 subjects will be randomised to receive gabapentin and tramadol placebo or tramadol and gabapentin placebo throughout 16\u201319 weeks (including 3 weeks of titration [optimisation period], 12 weeks of treatment at a stable dose [maintenance period] and 1\u20134 weeks of tapering [discontinuation period]). The primary objective is to assess the efficacy of gabapentin relative to tramadol for the treatment of moderate to severe chronic neuropathic or mixed pain by comparing the difference in average pain scores (assessed by age-appropriate pain scales) between intervention arms after 15 weeks of treatment. Secondary objectives include the assessment of the safety, quality of life and global satisfaction with treatment and the description of the pharmacokinetic\u2013pharmacodynamic relationship of gabapentin liquid formulation and tramadol oral drops to validate the recommended paediatric doses. Only rescue pain medication by paracetamol and\/or ibuprofen is allowed during the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethic approval was obtained in the eight participating countries. Results will be submitted for publication in a peer-reviewed journal and presented at one or more scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      2014-004851-30 and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT02722603\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\">NCT02722603<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial status<\/jats:title>\n                    <jats:p>Ongoing research study, currently recruiting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-023296","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T13:55:22Z","timestamp":1550670922000},"page":"e023296","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial\u2014a study protocol"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02722603","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-5602","authenticated-orcid":false,"given":"Florentia","family":"Kaguelidou","sequence":"first","affiliation":[{"name":"Department of Paediatric Pharmacology and Pharmacogenetics, AP-HP, H\u00f4pital Robert Debr\u00e9, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"Inserm, CIC 1426, F-75019, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enora","family":"Le Roux","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Robert Debr\u00e9, Unit\u00e9 d\u2019Epid\u00e9miologie Clinique, Paris, France"},{"name":"UMR-1123 ECEVE, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mangiarini","sequence":"additional","affiliation":[{"name":"PHARM \u2013 Pharmaceutical Research Management SRL, Lodi, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lundin","sequence":"additional","affiliation":[{"name":"Fondazione Penta Onlus, Padova, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G","family":"de Leeuw","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Erasmus MC Sophia Children\u2019s Hospital & Center for Pain Medicine Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Therapeutics Group, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Felisi","sequence":"additional","affiliation":[{"name":"PHARM \u2013 Pharmaceutical Research Management SRL, Lodi, Italy"},{"name":"CVBF\u2013Consorzio per le Valutazioni Biologiche e Farmacologiche, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"PHARM \u2013 Pharmaceutical Research Management SRL, Lodi, Italy"},{"name":"CVBF\u2013Consorzio per le Valutazioni Biologiche e Farmacologiche, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Tibboel","sequence":"additional","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Ceci","sequence":"additional","affiliation":[{"name":"Fondazione per la Ricerca Farmacologica Gianni Benzi onlus, Valenzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia N","family":"de Wildt","sequence":"additional","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"},{"name":"Department of Pharmacology and Toxicology, Radboud Universiteit Faculteit der Rechtsgeleerdheid, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Alberti","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"AP-HP, H\u00f4pital Robert Debr\u00e9, Unit\u00e9 d\u2019Epid\u00e9miologie Clinique, Paris, France"},{"name":"Inserm, U1123 and CICEC 1426, F-75019, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"2025121523544473000_9.2.e023296.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.06.017"},{"key":"2025121523544473000_9.2.e023296.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.07.031"},{"key":"2025121523544473000_9.2.e023296.3","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304208"},{"key":"2025121523544473000_9.2.e023296.4","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1526-4637.2010.00910.x","article-title":"Plasticity of complex regional pain syndrome (CRPS) in children","volume":"11","author":"Stanton-Hicks","year":"2010","journal-title":"Pain Med"},{"key":"2025121523544473000_9.2.e023296.5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.expneurol.2015.07.013","article-title":"Nerve injury and neuropathic pain - A question of age","volume":"275","author":"Fitzgerald","year":"2016","journal-title":"Exp Neurol"},{"key":"2025121523544473000_9.2.e023296.6","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0647"},{"key":"2025121523544473000_9.2.e023296.7","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-010-0115-9"},{"key":"2025121523544473000_9.2.e023296.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.11.027"},{"key":"2025121523544473000_9.2.e023296.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2025121523544473000_9.2.e023296.10","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0649"},{"key":"2025121523544473000_9.2.e023296.11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ejp.1137","article-title":"The research gap in chronic paediatric pain: a systematic review of randomised controlled trials","volume":"22","author":"Boulkedid","year":"2018","journal-title":"Eur J Pain"},{"key":"2025121523544473000_9.2.e023296.12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.arcped.2011.05.016","article-title":"[Management of neuropathic pain in children: guidelines for good clinical practice]","volume":"18","author":"Fournier-Charri\u00e8re","year":"2011","journal-title":"Arch Pediatr"},{"key":"2025121523544473000_9.2.e023296.13","article-title":"Opioids for neuropathic pain","volume":"3","author":"Eisenberg","year":"2006","journal-title":"The Cochrane database of systematic reviews"},{"key":"2025121523544473000_9.2.e023296.14","article-title":"Tramadol for neuropathic pain","volume":"2","author":"Duhmke","year":"2004","journal-title":"The Cochrane database of systematic reviews"},{"key":"2025121523544473000_9.2.e023296.15","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume":"3","author":"Moore","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"key":"2025121523544473000_9.2.e023296.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.482"},{"key":"2025121523544473000_9.2.e023296.17","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199812000-00014"},{"key":"2025121523544473000_9.2.e023296.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00243-8"},{"key":"2025121523544473000_9.2.e023296.19","unstructured":"World Health Organization (WHO). Persisting pain in children package: WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, 2012."},{"key":"2025121523544473000_9.2.e023296.20","unstructured":"GAPP. Gabapentin in pediatric pain. https:\/\/www.pediatricpain.eu\/ (Accessed 18 February 2018)."},{"key":"2025121523544473000_9.2.e023296.21","unstructured":"PDCO Opinion P\/0250\/2015. EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for gabapentin (EMEA-001310-PIP01-12-M02). http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/pips\/EMEA-001310-PIP01-12-M02\/pip_001009.jsp&mid=WC0b01ac058001d129 (Accessed 18 Feb 2018)."},{"key":"2025121523544473000_9.2.e023296.22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3591"},{"key":"2025121523544473000_9.2.e023296.23","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000282763.29778.59"},{"key":"2025121523544473000_9.2.e023296.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.04.030"},{"key":"2025121523544473000_9.2.e023296.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00169.x"},{"key":"2025121523544473000_9.2.e023296.26","unstructured":"Merskey H , Bogduk N . International association for the study of pain classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms: (SeattleIASP Press), 1994."},{"key":"2025121523544473000_9.2.e023296.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.04.007"},{"key":"2025121523544473000_9.2.e023296.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0974-3"},{"key":"2025121523544473000_9.2.e023296.29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jcph.708","article-title":"Sampling optimization in pharmacokinetic bridging studies: example of the use of deferiprone in children with \u03b2-thalassemia","volume":"56","author":"Bellanti","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2025121523544473000_9.2.e023296.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.12.004"},{"key":"2025121523544473000_9.2.e023296.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00311-4"},{"key":"2025121523544473000_9.2.e023296.32","first-page":"109","article-title":"Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study","volume":"49","author":"Payne","year":"2002","journal-title":"Anesth Prog"},{"key":"2025121523544473000_9.2.e023296.33","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9049-7"},{"key":"2025121523544473000_9.2.e023296.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0379-0738(03)00100-2"},{"key":"2025121523544473000_9.2.e023296.35","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen405"},{"key":"2025121523544473000_9.2.e023296.36","first-page":"293","article-title":"The FLACC: a behavioral scale for scoring postoperative pain in young children","volume":"23","author":"Merkel","year":"1997","journal-title":"Pediatr Nurs"},{"key":"2025121523544473000_9.2.e023296.37","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90018-9"},{"key":"2025121523544473000_9.2.e023296.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00314-1"},{"key":"2025121523544473000_9.2.e023296.39","unstructured":"pedsql. The PedsQL Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. http:\/\/www.pedsql.org\/."},{"key":"2025121523544473000_9.2.e023296.40","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"2025121523544473000_9.2.e023296.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmpt.2003.11.003"},{"key":"2025121523544473000_9.2.e023296.42","unstructured":"American Academy of Pediatrics. Addressing mental health concerns in primary care: a clinician\u2019s toolkit: American Academy of Pediatrics, 2010."},{"key":"2025121523544473000_9.2.e023296.43","doi-asserted-by":"crossref","unstructured":"Oquendo MA , Halberstam B , Mann JJ . Risk factors for suicidal behavior: utility and limitations of research instruments. Standardized evaluation in clinical practice. 1st edn, 2003:103\u201330.","DOI":"10.1176\/appi.books.9781615377268.lg04"},{"key":"2025121523544473000_9.2.e023296.44","first-page":"140","article-title":"Clinical validation of FLACC: preverbal patient pain scale","volume":"29","author":"Manworren","year":"2003","journal-title":"Pediatr Nurs"},{"key":"2025121523544473000_9.2.e023296.45","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181b85f98"},{"key":"2025121523544473000_9.2.e023296.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2005.01687.x"},{"key":"2025121523544473000_9.2.e023296.47","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200301000-00016"},{"key":"2025121523544473000_9.2.e023296.48","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e318203f495"},{"key":"2025121523544473000_9.2.e023296.49","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/10543406.2013.789893","article-title":"Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints","volume":"23","author":"Hida","year":"2013","journal-title":"J Biopharm Stat"},{"key":"2025121523544473000_9.2.e023296.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.02.006"},{"key":"2025121523544473000_9.2.e023296.51","unstructured":"Neurontin SPC. Neurontin and Associated names. INN- Gabapentin. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Neurontin_30\/WC500009308.pdf (Accessed on 18 Feb 2018)."},{"key":"2025121523544473000_9.2.e023296.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00833.x"},{"key":"2025121523544473000_9.2.e023296.53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0920-1211(99)00063-7","article-title":"Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety","volume":"38","author":"Korn-Merker","year":"2000","journal-title":"Epilepsy Res"},{"key":"2025121523544473000_9.2.e023296.54","doi-asserted-by":"publisher","DOI":"10.1177\/088307389601100611"},{"key":"2025121523544473000_9.2.e023296.55","unstructured":"Tramadol drops SPC. Summary of product characteristics. https:\/\/db.cbg-meb.nl\/mri\/spc\/nlh-0598-001.pdf (Accessed on 18 Feb 2018)."},{"key":"2025121523544473000_9.2.e023296.56","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2673"},{"key":"2025121523544473000_9.2.e023296.57","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/88.2.241"},{"key":"2025121523544473000_9.2.e023296.58","unstructured":"Healy P , Della Pasqua O . Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children. 2017 www.page-meeting.org\/?abstract=7358"},{"key":"2025121523544473000_9.2.e023296.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.10.006"},{"key":"2025121523544473000_9.2.e023296.60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.87802"},{"key":"2025121523544473000_9.2.e023296.61","unstructured":"EMEA. Committee for Medicinal Products for Human Use (CHMP). Guideline on reporting the results of population pharmacokinetic analyses, CHMP\/EWP\/185990\/06, 21 June 2007. 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003067.pdf (Accessed 18 Feb 2018)."},{"key":"2025121523544473000_9.2.e023296.62","unstructured":"Core Team R . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing., 2014."},{"key":"2025121523544473000_9.2.e023296.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.07.016"},{"key":"2025121523544473000_9.2.e023296.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.02.018"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-023296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:54:59Z","timestamp":1765871699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-023296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,20]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bmjopen-2018-023296"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-023296","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}